Two genes cooperate to trigger leukemia development

Congratulations to the international group of researchers led by HemaSphere Editor-in-Chief Prof.

EHA response to the EU’s Pharma Revision

Last week, the European Affairs team finalised EHA's response to the proposed revision of the EU (European Union) Pharmaceutical Legislation. In April 2023, the European Commission published a proposed Directive and Regulation to replace the current, outdated legal framework.

Genetic Predisposition to Blood Cancer (Rare diseases)

The objectives of the group are:

Share and extend clinical knowledge on the diagnosis and treatment of hematologic malignancies with germline predisposition.

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

EHA and EBMT joint meeting on CAR T cells, first of its kind in Europe

The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) will hold the first European CAR T Cell Meeting together in Paris on February 14-16, 2019.

Press Release "Crucial Directives must be revised to protect patients' interests and improve access to treatment"

This was a key message of a two-day conference, “Haematology and the next European decade”, hosted by the European Parliament and attended by doctors, researchers, parliamentarians, patients’ organisations and Commission officials.

EHA Statement on COVID-19 Vaccines

EHA-SHRC Hematology Tutorial on Thalassemia

Dates: May 10-11, 2018
Location: Shiraz, Iran
Chairs: M Karimi, MD Cappellini & A Taher

  

EHA in close collaboration with Shiraz Hematology Research Center and the Shiraz Medical Center, endorsed by the Iranian Pediatric Hematology Oncology Society, organize a two day tutorial on “Thalassemia”.…

EHA undersigns Manifesto on Treatment Optimization

EHA has given its formal endorsement to the “Manifesto for a new approach for better medicine in Europe: Establishing Treatment Optimization as part of personalized medicine development”.

Position of EHA on Clinical Trials

 

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.